POLYFLEX DIN 00849405
Status: Marketed
Holder: BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC.
Molecule: AMPICILLIN (AMPICILLIN TRIHYDRATE)
Health Canada record
| Active ingredient(s) | AMPICILLIN (AMPICILLIN TRIHYDRATE) 25 G |
|---|---|
| Dosage form | Powder For Suspension |
| Route | Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 31-Dec-1990 |
| Current status date | 08-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Boehringer Ingelheim (Canada) Ltd Ltee — licence 100187, currently licensed, last inspection rating C (2025-03-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AMPICILLIN (AMPICILLIN TRIHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00020877 | TEVA-AMPICILLIN | TEVA CANADA LIMITED | Capsule | AMPICILLIN (AMPICILLIN TRIHYDRATE) 250 MG | Marketed |
| 00020885 | TEVA-AMPICILLIN | TEVA CANADA LIMITED | Capsule | AMPICILLIN (AMPICILLIN TRIHYDRATE) 500 MG | Marketed |
| 00857629 | POLYFLEX | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Powder For Suspension | AMPICILLIN (AMPICILLIN TRIHYDRATE) 10 G | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26072 | 2021-06-15 | Supplement to a New Drug Submission (SNDS) | Manufacturing Change |
| 26021 | 2021-06-08 | New Drug Submission (NDS) | CHANGE IN PRODUCT OWNERSHIP |
| 25510 | 2021-03-23 | Supplement to a New Drug Submission (SNDS) | ADDITION OF ANALTERNATE DRUG PRODUCT MANUFACTURING SITE, MANUFACTURING CHANGE |
| 22242 | 2019-06-06 | Supplement to a New Drug Submission (SNDS) | MANUFACTURING CHANGE |
| 19158 | 2017-04-13 | Supplement to a New Drug Submission (SNDS) | ADDITION OF MANUFACTURING SITE |
| 11766 | 2010-09-29 | New Drug Submission (NDS) | Change in ownership |
| 3629 | 2004-05-19 | New Drug Submission (NDS) | |
| 6107 | 2002-05-02 | Supplement to a New Drug Submission (SNDS) | ALTERNATE SOURCE OF ACTIVE INGREDIENT |
| 6887 | 1998-06-01 | New Drug Submission (NDS) |